Fierce Biotech

  1. KSQ boosts PARP inhibition in animal models of ovarian and breast cancers with USP1 inhibitor arlene.weintraub Fri, 10/23/2020 - 10:03
  2. Alnylam makes case for lumasiran in infants ahead of FDA ruling   ntaylor Fri, 10/23/2020 - 08:29
  3. Sirnaomics nabs a major $105M funding round for next stage of its RNA work badams Fri, 10/23/2020 - 07:55
  4. Convalescent plasma fails phase 2 in moderate COVID-19 patients ntaylor Fri, 10/23/2020 - 05:27
  5. Retrophin buys up Orphan Technologies, spending $90M on rare disease drug badams Fri, 10/23/2020 - 05:07